Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
The Lancet. Oncology|August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Genome Medicine|July 17, 2021
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer modelsDeepak Vangala, Swetlana Ladigan, Sven T Liffers, et al.
Journal of the National Cancer Institute|June 20, 2018
Novel Common Genetic Susceptibility Loci for Colorectal CancerStephanie L Schmit, Christopher K Edlund, Fredrick R Schumacher, et al.
Nature Communications|September 25, 2019
Publisher Correction: Shared heritability and functional enrichment across six solid cancersXia Jiang, Hilary K Finucane, Fredrick R Schumacher, et al.
Nature Communications|January 27, 2019
Shared heritability and functional enrichment across six solid cancersXia Jiang, Hilary K Finucane, Fredrick R Schumacher, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
The Lancet. Oncology|August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Genome Medicine|July 17, 2021
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer modelsDeepak Vangala, Swetlana Ladigan, Sven T Liffers, et al.
Journal of the National Cancer Institute|June 20, 2018
Novel Common Genetic Susceptibility Loci for Colorectal CancerStephanie L Schmit, Christopher K Edlund, Fredrick R Schumacher, et al.
Nature Communications|September 25, 2019
Publisher Correction: Shared heritability and functional enrichment across six solid cancersXia Jiang, Hilary K Finucane, Fredrick R Schumacher, et al.
Nature Communications|January 27, 2019
Shared heritability and functional enrichment across six solid cancersXia Jiang, Hilary K Finucane, Fredrick R Schumacher, et al.
Pageof 21